Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bococizumab · RN-316

Monoclonal antibody · Acts on proprotein convertase subtilisin/kexin type 9 (PCSK9) · developed by Pfizer

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Bococizumab?

Bococizumab is a monoclonal antibody given subcutaneously at 300 mg.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RN-316
Drug type
Monoclonal antibody
Targets
proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism
Acts on proprotein convertase subtilisin/kexin type 9 (PCSK9)
Therapy area
Metabolic
Developer
Pfizer
In trials of
HALO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
45M75JVK38

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02667223 Phase 1 Healthy Terminated HALO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyHypercholesterolemia

Other drugs acting on PCSK9

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.